Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AcroImmune
Nanjing, Jiangsu, Chinaacroimmune.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
AcroImmune developed a pipeline of best-in-class and first-in-class immunotherapies targeting solid tumors and inflammatory diseases, including bispecific antibodies like PD‑1/VEGF-targeting AI‑081, with several programs at or near the IND-filing or early clinical stages. The company was acquired by OncoC4 in September 2024 to expand the combined immunotherapy pipeline and manufacturing capabilities.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Monoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugate (ADC)Other biologics
- Industry
- Biotech
02
Partnerships
Close relationship with OncoC4 Inc.; no major external pharma partnerships disclosed publicly.
Beyond the preview
Go deeper on AcroImmune.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AcroImmune.